Form 4: BioXcel Director Granted 17,000 Stock Options

BioXcel Therapeutics Director Peter Mueller received a grant of 17,000 stock options with an exercise price of $2.01, vesting over one year or by the next annual meeting.

Summary

• Peter Mueller, a Director of BioXcel Therapeutics, Inc. (BTAI), was granted 17,000 stock options.
• The options have an exercise price of $2.01 per share.
• The grant date for these options was January 9, 2026.
• The options will vest and become exercisable on the earlier of the first anniversary of the grant date or the day immediately prior to the next annual meeting of the Issuer's stockholders.
• Vesting is contingent upon Mr. Mueller's continued service as a non-employee director through the vesting date.
• The options have an expiration date of January 9, 2036.
• Following this transaction, Mr. Mueller beneficially owns 17,000 derivative securities directly.

Sentiment

Score: 6

Explanation: This filing reports a routine equity grant to a director, which is generally viewed as a neutral to slightly positive event as it aligns management incentives with shareholder interests. It does not indicate any significant operational or financial changes.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice for non-employee directors, reflecting a common approach to corporate governance and talent retention.

Negatives

• The exercise of these options in the future could lead to a slight dilution of existing shareholders' equity, although the amount is relatively small in this instance.

Risks

• The value of the stock options is dependent on the future market price of BioXcel Therapeutics' common stock exceeding the exercise price of $2.01.
• The options are subject to forfeiture if the reporting person ceases to serve as a non-employee director before the vesting conditions are met.
• Market volatility could impact the potential profitability of these options.

Future Outlook

The grant of stock options provides a future incentive for the director, aligning their long-term interests with the company's performance and shareholder value creation, contingent on continued service and stock price appreciation.

Industry Context

The grant of stock options to a non-employee director is a common practice within the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to attract and retain talent and align their interests with long-term company success.

Comparison to Industry Standards

• Equity compensation, such as stock options, for non-employee directors is a widely accepted practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule, tied to either a one-year anniversary or the next annual meeting, is a typical structure designed to ensure continued service and commitment from board members.
• The exercise price being set at the market price on the grant date is standard for incentive stock options, ensuring that the director benefits only if the company's stock price appreciates.

Corporate Governance

Related Party Transactions

• The grant of 17,000 stock options to Peter Mueller, a director of BioXcel Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon exercise of options, but also benefit from aligned director incentives for long-term company performance.
• Director (Peter Mueller): Receives equity compensation, providing a direct financial incentive tied to the company's stock price appreciation and continued service.

Next Steps

• The stock options will vest according to the specified schedule (earlier of first anniversary of grant or day prior to next annual meeting), subject to the director's continued service.
• Upon vesting, the director will have the ability to exercise these options at the stated exercise price of $2.01 per share until the expiration date.

Key Dates

Keywords

BioXcel Therapeutics, BTAI, Peter Mueller, Stock Options, Director Compensation, SEC Form 4, Equity Grant, Insider Transaction, Vesting